XENT Intersect ENT Inc

Intersect ENT to Present at the 36th Annual J.P. Morgan Healthcare Conference

MENLO PARK, Calif.--(BUSINESS WIRE)--

Intersect ENT, Inc. (Nasdaq: XENT), today announced that management will present an overview of the company's business at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2018 at 2:30 p.m. PT at the Westin St. Francis Hotel.

A live webcast of the presentation will be available online from the Investor Relations page of the Company's website at http://www.intersectENT.com. The webcast replay will be available for approximately one month.

About Intersect ENT®

Intersect ENT is dedicated to transforming the landscape of care for patients with ear, nose and throat conditions. The company’s PROPEL® family of dissolvable steroid releasing sinus implants are clinically proven to improve outcomes for chronic sinusitis patients undergoing sinus surgery. In addition, Intersect ENT is continuing to expand its portfolio of products based on the company’s unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost effective care.

For additional information on the company or the products including risks and benefits please visit www.IntersectENT.com.

Intersect ENT® and PROPEL® are registered trademarks and SINUVA is a trademark of Intersect ENT, Inc.

XENT-F

EN
07/12/2017

Underlying

XENTIntersect ENT Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Intersect ENT Inc

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
COP CONOCOPHILLIPS
MTB M&T BANK CORPOR... ... (+46)

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

COP CONOCOPHILLIPS
MTB M&T BANK CORPORATION
XENT INTERSECT ENT INC
WDAY WORKDAY INC. CLASS A
TXRH TEXAS ROADHOUSE INC.
TPRE SIRIUSPOINT LTD
SQ SQUARE INC. CLASS A
SIG SIGNET JEWELERS LIMITED
RVNC REVANCE THERAPEUTICS INC.
RGNX REGENXBIO INC.
NRZ NEW RESIDENTIAL INVESTMENT CORP.
NGVC NATURAL GROCERS BY VITAMIN COTTAGE INC
NDLS NOODLES & COMPANY
MYL VIATRIS INC.
LMNX LUMINEX CORP
HRTX HERON THERAPEUTICS INC
HAL HALLIBURTON COMPANY
FRGI FIESTA RESTAURANT GROUP INC.
FFNW FIRST FINANCIAL NORTHWEST INC.
EWBC EAST WEST BANCORP INC.
DDD 3D SYSTEMS CORPORATION
BYD BOYD GAMING CORPORATION
ARR ARMOUR RESIDENTIAL REIT INC.
APA.. APA CORP.
RRR RED ROCK RESORTS INC. CLASS A
FMAO FARMERS & MERCHANTS BANCORP INC.
IIIN INSTEEL INDUSTRIES INC.
AAOI APPLIED OPTOELECTRONICS INC.
CAH CARDINAL HEALTH INC.
CENT CENTRAL GARDEN & PET COMPANY
MBUU MALIBU BOATS INC. CLASS A
PETS PETMED EXPRESS INC.
AC ASSOCIATED CAPITAL GROUP
INBK FIRST INTERNET BANCORP
CWH CAMPING WORLD HOLDINGS INC. CLASS A
TVTY TIVITY HEALTH INC.
AOBC SMITH & WESSON BRANDS INC.
BY BYLINE BANCORP
EYE NATIONAL VISION HOLDINGS
SPB SPECTRUM BRANDS HOLDINGS INC.
AVRO AVROBIO
EB EVENTBRITE
MRNA MODERNA INC.
CNR CORNERSTONE BUILDING BRANDS INC
MCFT MASTERCRAFT BOAT HOLDINGS
USX U.S. XPRESS ENTERPRISES
02/02/20 February 2, 2020 25 EN
Free Trial
XENT Intersect ENT I...

1 director sold after exercising options/sold

A director at Intersect Ent Inc sold after exercising options/sold 29,588 shares at 28.432USD and the significance rating of the trade was 81/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors...

XENT INTERSECT ENT INC
04/17/19 April 17, 2019 1 EN
 PRESS RELEASE
Free
XENT Intersect ENT I...

Intersect ENT Reports First Quarter 2018 Results

MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported financial results for the first quarter ended March 31, 2018. Recent Business Highlights In April 2018, the company announced U.S. commercial availability of SINUVA™ Sinus Implant, a new in-office treatment option for recurrent nasal polyps. Placed during a routine doctor’s office visit under local or topical anesthesia, SINUVA ...

May 1, 2018 1 EN
 PRESS RELEASE
Free
XENT Intersect ENT I...

Intersect ENT to Present at Deutsche Bank and Bank of America Merrill ...

MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (Nasdaq: XENT) today announced that management will present at Deutsche Bank’s 43rd Annual Health Care Conference and at Bank of America Merrill Lynch 2018 Healthcare Conference. The Deutsche Bank Conference presentation is scheduled for May 9, 2018 at 10:40am EDT at the Boston InterContinental Hotel and the Bank of America Merrill Lynch presentation is scheduled for May 16, 2018 at 4:00pm EDT at the Encore at The Wynn in Las Vegas. A webcast of both pr...

April 17, 2018 1 EN
 PRESS RELEASE
Free
XENT Intersect ENT I...

Intersect ENT to Report First Quarter 2018 Financial Results

MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ:XENT), a company seeking to improve the quality of life for patients with ear, nose and throat conditions, today announced that it will release financial results for its first quarter on May 1, 2018. The company expects to issue the release at approximately 4:00 p.m. ET and management will host a conference call at 4:30 p.m. ET that same day. To access the conference call via the internet, go to the "Investor Relations" page of the company's web site at www.int...

April 16, 2018 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch